Trial Profile

Effect of UGT Genetic Variation on Pharmacokinetics of Empagliflozine

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary)
Indications Acute heart failure; Cardiovascular disorders; Chronic heart failure; Decompensated heart failure; Gestational diabetes; Heart failure; Insulin resistance; Renal failure; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Focus Pharmacokinetics

Most Recent Events

12 Feb 2023 Status changed from not yet recruiting to completed.
05 Feb 2022 Planned End Date changed from 1 Feb 2022 to 1 May 2022.
05 Feb 2022 Planned primary completion date changed from 1 Feb 2022 to 1 May 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com